There are currently 24 ongoing clinical trials involving Fragile X Syndrome
Of the 24 trials,7 trials are in Phase II/III
Furthermore, 6 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Fragile X Syndrome, a Genetic Disorder condition. The largest number of ongoing clinical trials for Fragile X Syndrome is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Fragile X Syndrome-related drug trials.
Zynerba Pharmaceuticals Inc: The leading ongoing Fragile X Syndrome related clinical trial sponsor
Zynerba Pharmaceuticals Inc is the top sponsor for Fragile X Syndrome-related ongoing clinical trials.
Puretech Health Plc, Rowan University, Shionogi & Co Ltd, Autifony Therapeutics Ltd, and University of California Davis are among other notable clinical trial sponsors involved in Fragile X Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer